Skip to main navigation Investors Corporate Profile Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir™, Seprehvec™) and a Tyrosine Kinase Inhibitor (Abivertinib). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVIGUARD™, COVISHIELD™, COVI-AMG™, COVIDROPS™, SALICYN – 30 and MESENCHYMAL STEM CELL; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™. Sorrento's commitment to developing and commercializing medicines for Saving-Life™ and Improving-Life™ is also demonstrated by our efforts to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and by ZTlido® (lidocaine topical system) 1.8%, for post-herpetic neuralgia (PHN). Resiniferatoxin is completing (i) a phase IB trial for intractable pain associated with cancer; and (ii) a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018. Stock Quote Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest News Nov 22, 2021 Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market Nov 12, 2021 Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City Nov 12, 2021 Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research View All News VIEW ALL Events Jan 4, 2022 from 5:00 PM to 5:30 PM EST H.C. Wainwright BioConnect Virtual Conference Dec 1, 2021 from 3:30 PM to 3:50 PM EST Evercore ISI 4th Annual HealthCONx Virtual Conference Sep 29, 2021 at 9:20 AM EDT 2021 Cantor Virtual Global Healthcare Conference Click here for webcast View All Events VIEW ALL Tools PRINT EMAIL ALERTS RSS FEEDS EMAIL PAGE © 2021 Sorrento Therapeutics. All Rights Reserved. Footer Terms of Use Privacy Policy DMCA Trademarks Linking Policy